NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News, & Analysis

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Cellular Biomedicine Group declared that its Board of Directors has initiated a stock repurchase program on Sunday, June 4th 2017, which permits the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company's board believes its stock is undervalued.

Cellular Biomedicine Group Inc (NASDAQ:CBMG) posted its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by $0.04. The biotechnology company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative net margin of 13,988.39% and a negative return on equity of 44.62%. View Cellular Biomedicine Group's Earnings History.

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Cellular Biomedicine Group.

3 Wall Street analysts have issued 12 month price objectives for Cellular Biomedicine Group's stock. Their forecasts range from $26.00 to $38.00. On average, they anticipate Cellular Biomedicine Group's share price to reach $32.00 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

Media stories about CBMG stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.

Some companies that are related to Cellular Biomedicine Group include Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL), Novavax (NVAX) and BAVARIAN NORDIC/S (BVNRY).

Cellular Biomedicine Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.58%), Northern Trust Corp (0.88%), Geode Capital Management LLC (0.69%), Bank of New York Mellon Corp (0.21%), Rhumbline Advisers (0.08%) and Bank of America Corp DE (0.06%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

CBMG stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Cellular Biomedicine Group.

CBMG stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Bank of America Corp DE, MetLife Investment Advisors LLC, Bank of New York Mellon Corp, Rhumbline Advisers, Metropolitan Life Insurance Co. NY and Meeder Asset Management Inc.. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBMG stock can currently be purchased for approximately $19.56.

Cellular Biomedicine Group has a market capitalization of $359.85 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com.

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]